Abstract:Factor VIII (FVIII) is the protein defective in the bleeding disorder hemophilia A. Approximately 5% of hemophilia A patients have normal amounts of a dysfunctional FVIII protein and are termed cross-reacting material (CRM)-positive. The majority of genetic alterations that result in CRM-positive hemophilia A are missense mutations within the A2-domain. To determine the mechanistic basis of the genetic defects within the A2-domain for FVIII function we constructed six mutations within the FVIII cDNA that were previously found in five CRM-positive hemophilia A patients (R527W, S558F, I566T, V634A, and V634M) and one CRM-reduced hemophilia A patient (DeltaF652/3). The specific activity for each mutant secreted into the conditioned medium from transiently transfected COS-1 cells correlated with published data for the patients plasma-derived FVIII, confirming the basis of the genetic defect. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of immunoprecipitated FVIII protein radiolabeled in COS-1 cells showed that all CRM-positive mutant proteins were synthesized and secreted into the medium at rates similar to wild-type FVIII. The majority of the DeltaF652/3 mutant was defective in secretion and was degraded within the cell. All mutant FVIII proteins were susceptible to thrombin cleavage, and the A2-domain fragment from the I566T mutant had a reduced mobility because of use of an introduced potential N-linked glycosylation site that was confirmed by N-glycanase digestion. To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site. The concentration of peptide required for 50% inhibition of FVIII activity (IC50) was reduced for the I566T (800 mumol/L) and the S558F (960 mumol/L) mutants compared with wild-type FVIII (> 2,000 mumol/L). N-glycanase digestion increased I566T mutant FVIII activity and increased its IC50 for the peptide (1,400 mumol/L). In comparison to S558F, a more conservative mutant (S558A) had a sixfold increased specific activity that also correlated with an increased IC50 for the peptide. These results provided support that the defects in the I566T and S558F FVIII molecules are caused by steric hindrance for interaction with factor IXa.

Crystal Structure of Human Factor VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex

Trp(2313)-His(2315) Of Factor Viii C2 Domain Is Involved In Membrane Binding Structure Of A Complex Between The C2 Domain And An Inhibitor Of Membrane Binding

Trp2313-His2315 of Factor VIII C2 Domain is Involved in Membrane Binding

Crystal Structure of the Calcium-Stabilized Human Factor IX Gla Domain Bound to a Conformation-Specific Anti-Factor IX Antibody.

The Protein Structure and Effect of Factor Viii

Crystallization of an Anti-Factor IX Antibody and Its Complex.

Blood coagulation factor IX: structural insights impacting hemophilia B therapy

The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII

Crystal Structure Of The Fab Fragment Of An Anti-Factor Ix Antibody 10c12

Partial reconstitution of factor VIII activity from a mild Crm+ hemophilia A patient by replacement of the defective A2 domain

Human coagulation factor IX: a systematic review of its characteristics

Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies

Inherited factor X deficiency: molecular genetics and pathophysiology

Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.

Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking

Crystal Structure, Epitope, and Functional Impact of an Antibody Against a Superactive FVIIa Provide Insights into Allosteric Mechanism

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts

Crystal Structure of Extracellular Domain of Tissue Factor Complexes with an Inhibitory Fab.

Dimer dissociation and unfolding mechanism of coagulation factor XI apple 4 domain: spectroscopic and mutational analysis

Factor XI Homodimer Structure is Essential for Normal Proteolytic Activation by Factor XIIa, Thrombin, and Factor XIa.

Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors